Background: Primary-care veterinary clinical records can offer data to determine generalizable epidemiological data on seizures occurrence in the dog population.
Objectives: To identify and examine epidemiologic characteristics of seizure occurrence in dogs under primary veterinary care in the UK participating in the VetCompass™ Programme.
Animals: 455,553 dogs in VetCompass™'.
Methods: A cross-sectional analysis estimated the 1-year period prevalence and risk factors for dogs with seizures during 2013.
Results: The overall 1-year period prevalence for dogs having at least one seizure during 2013 was 0.82% (95% CI 0.79-0.84). Multivariable modelling identified breeds with elevated odd ratios [OR] compared with the Labrador Retriever (e.g. Pug OR: 3.41 95% CI 2.71-4.28, P < 0.001). Males had higher risk for seizures (Male/Entire OR: 1.47 95% CI 1.30-1.66; Male/Neutered OR: 1.34 95% CI 1.19-1.51) compared to entire females. Age (3.00 - ≤ 6.00 OR: 2.13 95% CI 1.90-2.39, P < 0.001, compared to animals aged 0.50-≤ 3.00 years), and bodyweight (≥ 40.00kg, OR: 1.24 95% CI 1.08-1.41, P = 0.002, compared to animals weighing < 10.0 kg) were identified as risk factors for seizures.
Conclusion And Clinical Importance: Seizures are a relatively common clinical finding in dogs. The results for breed, age, sex and bodyweight as risk factors can assist veterinarians in refining differential diagnosis lists for dogs reported with behaviors that may have been seizures. In addition, the prevalence values reported here can support pharmacovigilance with baseline data from the overall population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189390 | PMC |
http://dx.doi.org/10.1111/jvim.15290 | DOI Listing |
Gastric Cancer
January 2025
Department of Medical Oncology, Hospital Clinico Universitario, INCLIVA, Biomedical Research Institute, University of Valencia, Avenida Menendez Pelayo nro 4 accesorio, Valencia, Spain.
Introduction: Gastric cancer (GC) burden is currently evolving with regional differences associated with complex behavioural, environmental, and genetic risk factors. The LEGACy study is a Horizon 2020-funded multi-institutional research project conducted prospectively to provide comprehensive data on the tumour biological characteristics of gastroesophageal cancer from European and LATAM countries.
Material And Methods: Treatment-naïve advanced gastroesophageal adenocarcinoma patients were prospectively recruited in seven European and LATAM countries.
Breast Cancer Res Treat
January 2025
Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Purpose: There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.
Methods: We obtained characteristics and survival data from 206,156 YBC patients (≤ 40 years of age) diagnosed between 2005 and 2019 from the National Cancer Database (NCDB). Patients were subdivided into two comparison groups based on year of diagnosis (2005-2009, Old vs.
Am J Sports Med
January 2025
Department of Pharmacology and Biostatistics, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Background: Patellar instability is frequently encountered by orthopaedic surgeons. One of the major risk factors of this condition is underlying trochlear dysplasia (TD). Recent trends have indicated the use of multiple procedures to correct patellar instability under these conditions.
View Article and Find Full Text PDFClin Exp Nephrol
January 2025
Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-Ku, Saitama, Saitama, 330-8777, Japan.
CNS Drugs
January 2025
Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Background: Early neurological deterioration (END) is associated with a poor prognosis in acute ischemic stroke (AIS). Effectively lowering low-density lipoprotein cholesterol (LDL-C) can improve the stability of atherosclerotic plaque and reduce post-stroke inflammation, which may be an effective means to lower the incidence of END. The objective of this study was to determine the preventive effects of evolocumab on END in patients with non-cardiogenic AIS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!